AI
Friday, September 24, 2021 3:02:57 PM
hankmanhub, I am going to repeat some of what I said earlier. Most of that money that NWBio has spent to buildout the Sawston facility, is on NWBio’s balance sheet as assets. Some of it is under Plant, Property & Equipment (PP&E), some under Construction in Progress, and some under Right -of-Use asset.
This is “much ado about nothing”. All of these assets are for the benefit of NWBO shareholders. NWBio own all of the Sawston equipment, and leasehold improvements in that facility, That includes all of the clean rooms. Cognate and Advent are only “a means to an end”. The primary reasons Cognate was started were:
(1) To help NWBio fulfill the FDA’s and Health Canada’s requirement to have licensed and approved GMP manufacturing capabilities to complete the DCVax-L Phase III clinical trial.
(2) Convince the FDA and Health Canada that NWBio would be able to produce enough DCVax-L, on a commercial scale, to justify regulatory approval of DCVax-L in the US and Canada.
(3) Protect the DCVax-L and DCVax Direct patents and other IP from rivals, and potential rivals, including Big Pharma
The primary reasons Advent was started were:
(1) Convince the EMA and MHRA that NWBio would be able to produce enough DCVax-L, on a commercial scale, to justify regulatory approval of DCVax-L in the UK, Germany and the rest of the EU.
(2) Protect the DCVax-L and DCVax Direct patents and other IP from rivals, and potential rivals, in Europe including Big Pharma.
Both Cognate and Advent have served, and are continuing to serve their purpose. Both Cognate and Advent have created a lot of NWBO value and gains for NWBO shareholders. It is unfortunate that some NWBO shareholders don’t acknowledge or understand these facts.
I, personally prefer that NWBio continue to focus on becoming a high margin, highly profitable biotech, by focusing on exploiting and maximizing the worldwide value of the DCVax-L and DCVax Direct vaccine platform, that has the potential to treat all or most solid tumor cancers, both operable and inoperable.
I am not interested in NWBio focusing on a lower margin, more capital intensive and more labor intensive industry, like becoming a CDMO.
This is “much ado about nothing”. All of these assets are for the benefit of NWBO shareholders. NWBio own all of the Sawston equipment, and leasehold improvements in that facility, That includes all of the clean rooms. Cognate and Advent are only “a means to an end”. The primary reasons Cognate was started were:
(1) To help NWBio fulfill the FDA’s and Health Canada’s requirement to have licensed and approved GMP manufacturing capabilities to complete the DCVax-L Phase III clinical trial.
(2) Convince the FDA and Health Canada that NWBio would be able to produce enough DCVax-L, on a commercial scale, to justify regulatory approval of DCVax-L in the US and Canada.
(3) Protect the DCVax-L and DCVax Direct patents and other IP from rivals, and potential rivals, including Big Pharma
The primary reasons Advent was started were:
(1) Convince the EMA and MHRA that NWBio would be able to produce enough DCVax-L, on a commercial scale, to justify regulatory approval of DCVax-L in the UK, Germany and the rest of the EU.
(2) Protect the DCVax-L and DCVax Direct patents and other IP from rivals, and potential rivals, in Europe including Big Pharma.
Both Cognate and Advent have served, and are continuing to serve their purpose. Both Cognate and Advent have created a lot of NWBO value and gains for NWBO shareholders. It is unfortunate that some NWBO shareholders don’t acknowledge or understand these facts.
I, personally prefer that NWBio continue to focus on becoming a high margin, highly profitable biotech, by focusing on exploiting and maximizing the worldwide value of the DCVax-L and DCVax Direct vaccine platform, that has the potential to treat all or most solid tumor cancers, both operable and inoperable.
I am not interested in NWBio focusing on a lower margin, more capital intensive and more labor intensive industry, like becoming a CDMO.
